EATRIS is happy to present the Annual Report for 2018, the fifth year of active operations for EATRIS ERIC. You will learn about the year’s highlights and notable milestones, presented in a more personal format, told by the passionate advocates of Translational Medicine in EATRIS.
As with all previous years in EATRIS short history as the European Infrastructure for Translational Medicine, the year was an exciting blend of growth, adaptation and maturation. Starting the year with Toni Andreu taking on the role as Scientific Director, under his guidance we finalised the Strategic Plan 2019-2022, the result of a wide consultation process with our key stakeholders. The product is a concise, robust and exciting programme designed to meet the needs of our community of users and members. A highlight of this is the special focus on supporting national community development and the initiation of the EATRIS Strategic Research & Innovation Agenda in support of that goal.
2018 also witnessed significant growth in EATRIS portfolio of services for academic users, to augment its sector-leading portfolio of industry services. As a result, EATRIS is enjoying rapid expansion of our active user base by supporting the development of ground-breaking therapies and diagnostics and translational tools. The development of imaging tools for the tracking of cell therapies in the body as seen in the EPPIC proposal is a highlight, along with the IMI selection towards second stage application of EU-PEARL, an ambitious proposal to develop a long-term framework for platform trials in a wide variety of disease areas.
Read more on EATRIS website: https://eatris.eu/insights/eatris-annual-report-2018/